ST天圣(002872) - 2017 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2017 was CNY 2,261,414,376.96, representing an increase of 8.36% compared to CNY 2,086,931,557.22 in 2016[15]. - The net profit attributable to shareholders for 2017 was CNY 248,575,376.84, which is a 10.73% increase from CNY 224,496,958.17 in 2016[15]. - The basic earnings per share for 2017 was CNY 1.310, down 7.09% from CNY 1.41 in 2016[15]. - The total assets at the end of 2017 were CNY 4,946,489,036.83, an increase of 45.83% from CNY 3,391,975,665.31 at the end of 2016[15]. - The net assets attributable to shareholders at the end of 2017 were CNY 3,133,096,280.85, up 73.54% from CNY 1,805,402,870.48 at the end of 2016[16]. - The weighted average return on equity for 2017 was 9.98%, down from 13.26% in 2016[15]. - The company achieved a total revenue of ¥2,261,414,376.96, representing an 8.36% increase compared to the previous year[32]. - The net profit attributable to shareholders reached ¥248,575,376.84, reflecting a growth of 10.73% year-over-year[32]. - The total assets of the company increased by 45.83% to ¥4,946,489,036.83 as of December 31, 2017[32]. Cash Flow and Investments - The net cash flow from operating activities for 2017 was negative CNY 55,748,598.61, a decline of 111.00% compared to CNY 506,677,240.37 in 2016[15]. - The net cash flow from operating activities showed significant fluctuation, with a negative cash flow of ¥146 million in Q2, but a positive cash flow of ¥212 million in Q4[20]. - Investment activities cash inflow increased by 897.04% to ¥317,559,843.79, while cash outflow rose by 198.56% to ¥1,271,749,426.86[50]. - The total investment amount for the reporting period was ¥1,271,749,426.86, representing a 198.56% increase from the previous year[59]. - The company’s cash and cash equivalents increased by 22.98% to ¥222,932,265.37[50]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 2.36 per 10 shares, totaling CNY 50,000,000 based on 212,000,000 shares[4]. - In 2017, the company distributed cash dividends totaling RMB 50,032,000, which accounted for 20.13% of the net profit attributable to shareholders of RMB 248,575,376.84[89]. - The cash dividend per 10 shares was RMB 2.36 (including tax), with a capital reserve conversion of 5 shares for every 10 shares held, increasing the total share capital from 212,000,000 to 318,000,000 shares[92]. - The company's distributable profit for 2017 was RMB 1,277,682,610.86, with cash dividends representing 100% of the profit distribution[90]. Research and Development - Research and development expenditure for 2017 was ¥33,857,937.24, which is 1.50% of the operating revenue[49]. - The company has a total of 94 R&D personnel, an increase of 18.99% from the previous year[49]. - The company is committed to increasing its R&D capabilities by establishing a drug research center and attracting high-level talent in medicine and pharmacy over the next three years[79]. Market and Competition - The company faces risks related to industry policy changes, market competition, and raw material price fluctuations[4]. - The company aims to enhance market competitiveness by integrating resources and optimizing product structure in the manufacturing sector[33]. - The company faces market competition risks, particularly from new entrants in the pharmaceutical manufacturing and distribution sectors, which could impact market share and profitability[80]. Corporate Governance and Compliance - The company has adhered to its profit distribution policy, ensuring stable returns for investors without any adjustments during the reporting period[86]. - The board of directors consists of 11 members, including 4 independent directors, ensuring a diverse and professional governance structure[175]. - The company maintains complete independence from its controlling shareholder in terms of business operations, personnel, assets, and finances[178][179]. - The company has implemented strict information disclosure practices to ensure transparency and timely communication with investors[177]. Subsidiaries and Expansion - The company expanded its operational scope by adding 11 new subsidiaries, bringing the total to 45[45]. - The company has established several subsidiaries during the reporting period, which had no significant impact on overall operations and performance[75]. - The company plans to expand production capacity for oral solid preparations, targeting an annual output of 600 million capsules, 400 million tablets, and 320 million bags of granules after the GMP technology renovation project is completed[77]. Environmental and Social Responsibility - The company has committed to environmental protection, ensuring that all major pollutant discharge indicators meet regulatory standards[134]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, and actively engages in social responsibility initiatives[132]. - The company invested 675,800 RMB in poverty alleviation initiatives during the reporting period, focusing on various poverty alleviation strategies[133]. Audit and Financial Reporting - The audit opinion type for the financial statements was a standard unqualified opinion, issued on April 20, 2018[197]. - The internal control audit report issued by Beijing Xinghua Certified Public Accountants confirmed the effectiveness of the company's internal controls as of December 31, 2017, in all material respects[193]. - The financial statements fairly present the financial position of the company as of December 31, 2017, and the operating results for the year 2017[198].